WO2022243913 - COMPOSITIONS AND METHODS FOR ENHANCING VISUAL FUNCTION
National phase entry is expected:
Publication Number
WO/2022/243913
Publication Date
24.11.2022
International Application No.
PCT/IB2022/054650
International Filing Date
19.05.2022
Title **
[English]
COMPOSITIONS AND METHODS FOR ENHANCING VISUAL FUNCTION
[French]
COMPOSITIONS ET PROCÉDÉS D'AMÉLIORATION DE LA FONCTION VISUELLE
Applicants **
NOVARTIS AG
Inventors
GUERIN, Karen I.
KOTIN, Robert M.
PASTOR, Eric
REN, Xiaozhi
YOUNG, Sharon
Priority Data
63/191,525
21.05.2021
US
63/292,746
22.12.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3928 | |
| EPO | Filing, Examination, Granting | 42174 | |
| Japan | Filing, Examination, Granting | 3649 | |
| South Korea | Filing, Examination, Granting | 5367 | |
| USA | Filing, Examination, Granting | 17390 |
Total:
72,508
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure provides compositions and methods of restoring or enhancing visual function in an individual by administering to the individual a pharmaceutical composition comprising a recombinant adeno-associated viral (rAAV) vector having a polynucleotide sequence that encodes a medium wavelength cone opsin (MW-opsin). The MW-opsin is expressed in a retinal cell in the individual, thereby restoring or enhancing visual function.[French]
La présente invention concerne des compositions et des procédés de restauration ou d'amélioration de la fonction visuelle chez un individu par administration à l'individu d'une composition pharmaceutique comprenant un vecteur de virus adéno-associé recombinant (rAAV) ayant une séquence polynucléotidique qui code pour une opsine de cône à longueur d'onde moyenne (MW-opsine). La MW-opsine est exprimée dans une cellule rétinienne chez l'individu, ce qui permet de restaurer ou d'améliorer la fonction visuelle.